• Mon espace de travail
  • Aide IRIS
  • Par Publication Par Personne Par Unité
    • English
    • Français
  • Se connecter
Logo du site

IRIS | Système d’Information de la Recherche Institutionnelle

  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
UNIL
  • English
  • Français
Se connecter
IRIS
  • Accueil
  • Personnes
  • Publications
  • Unités
  • Périodiques
  • Mon espace de travail
  • Aide IRIS

Parcourir IRIS

  • Par Publication
  • Par Personne
  • Par Unité
  1. Accueil
  2. IRIS
  3. Publication
  4. Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia.
 
  • Détails
Titre

Rapid Generation of TCR and CD8αβ Transgenic Virus Specific T Cells for Immunotherapy of Leukemia.

Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Frontiers in Immunology  
Auteur(s)
Bajwa, G.
Auteure/Auteur
Arber, C.
Auteure/Auteur
Liens vers les personnes
Arber, Caroline  
Liens vers les unités
Ludwig Lausanne Branch (LLB)  
Recherche en oncologie  
ISSN
1664-3224
Statut éditorial
Publié
Date de publication
2022
Volume
13
Première page
830021
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: epublish
Résumé
Virus-specific T cells (VSTs) are an attractive cell therapy platform for the delivery of tumor-targeted transgenic receptors. However, manufacturing with conventional methods may require several weeks and intensive handling. Here we evaluated the feasibility and timelines when combining IFN-γ cytokine capture (CC) with retroviral transduction for the generation of T cell receptor (TCR) and CD8αβ (TCR8) transgenic VSTs to simultaneously target several viral and tumor antigens in a single product.
Healthy donor peripheral blood mononuclear cells were stimulated with cytomegalovirus (CMV) and Epstein-Barr-Virus (EBV) peptide mixtures derived from immunogenic viral proteins, followed by CC bead selection. After 3 days in culture, cells were transduced with a retroviral vector encoding four genes (a survivin-specific αβTCR and CD8αβ). TCR8-transgenic or control VSTs were expanded and characterized for their phenotype, specificity and anti-viral and anti-tumor functions.
CC selected cells were efficiently transduced with TCR8. Average fold expansion was 269-fold in 10 days, and cells contained a high proportion of CD8+ T central memory cells. TCR8+ VSTs simultaneously expressed native anti-viral and transgenic anti-survivin TCRs on their cell surface. Both control and TCR8+ VSTs produced cytokines to and killed viral targets, while tumor targets were only recognized and killed by TCR8+ VSTs.
IFN-γ cytokine capture selects and activates CMV and EBV-specific memory precursor CD8+ T cells that can be efficiently gene-modified by retroviral transduction and rapidly ex vivo expanded. Our multi-specific T cells are polyfunctional and recognize and kill viral and leukemic targets expressing the cognate antigens.
Sujets

CD8 Antigens

Cytokines/metabolism

Cytomegalovirus

Cytomegalovirus Infec...

Herpesvirus 4, Human

Humans

Immunologic Factors

Immunotherapy

Leukemia

Leukocytes, Mononucle...

Receptors, Antigen, T...

cytokine capture

engineered T cells

immunotherapy

interferon-gamma

transgenic CD8

transgenic TCR

virus-specific T cell...

PID Serval
serval:BIB_0C6CE3A6605F
DOI
10.3389/fimmu.2022.830021
PMID
35572604
WOS
000795659100001
Permalien
https://iris.unil.ch/handle/iris/75126
Open Access
Oui
Date de création
2022-05-31T12:09:27.022Z
Date de création dans IRIS
2025-05-20T16:40:48Z
Fichier(s)
En cours de chargement...
Vignette d'image
Nom

35572604_BIB_0C6CE3A6605F.pdf

Version du manuscrit

published

Licence

https://creativecommons.org/licenses/by/4.0

Taille

7.35 MB

Format

Adobe PDF

PID Serval

serval:BIB_0C6CE3A6605F.P001

URN

urn:nbn:ch:serval-BIB_0C6CE3A6605F8

Somme de contrôle

(MD5):ae46d88d0ec96a8dfd434b84732d9bdb

  • Copyright © 2024 UNIL
  • Informations légales